In a filing, Adma Biologics Inc revealed its President and CEO Grossman Adam S unloaded Company’s shares for reported $0.39 million on Jul 15 ’25. In the deal valued at $18.66 per share,21,000 shares were sold. As a result of this transaction, Grossman Adam S now holds 2,037,850 shares worth roughly $34.09 million.
Then, Grossman Adam S bought 63,000 shares, generating $1,176,840 in total proceeds.
Before that, Grossman Adam S sold 21,000 shares. Adma Biologics Inc shares valued at $437,010 were divested by the President and CEO at a price of $20.81 per share. As a result of the transaction, Grossman Adam S now holds 2,043,850 shares, worth roughly $34.19 million.
A number of analysts have revised their coverage, including Mizuho’s analysts, who began to cover the stock in mid October with a ‘”a Buy”‘ rating. Raymond James also remained covering ADMA and has increased its forecast on November 11, 2021 with a “Strong buy” recommendation from previously “an Outperform” rating. Cantor Fitzgerald started covering the stock on November 09, 2021. It rated ADMA as “an Overweight”.
Price Performance Review of ADMA
On Friday, Adma Biologics Inc [NASDAQ:ADMA] saw its stock fall -4.89% to $16.73. Over the last five days, the stock has lost -9.62%. Adma Biologics Inc shares have risen nearly 21.85% since the year began. Nevertheless, the stocks have fallen -2.45% over the past one year. While a 52-week high of $25.67 was reached on 04/28/25, a 52-week low of $10.21 was recorded on 03/04/25.
Levels Of Support And Resistance For ADMA Stock
The 24-hour chart illustrates a support level at 16.26, which if violated will result in even more drops to 15.78. On the upside, there is a resistance level at 17.45. A further resistance level may holdings at 18.16.
How much short interest is there in Adma Biologics Inc?
A steep rise in short interest was recorded in Adma Biologics Inc stocks on 2025-06-13, growing by 0.47 million shares to a total of 13.81 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 13.33 million shares. There was a rise of 3.42%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on June 04, 2019 when Jefferies began covering the stock and recommended ‘”a Buy”‘ rating along with a $8 price target.
